A margetuximab agreement for MacroGenics and EVERSANA
MacroGenics and EVERSANA announce approval-dependent agreement to support launch and commercialization of margetuximab
Business & Policy News
Merck snaps up OncoImmune for $425M
The acquisition nets Merck a pipeline of oncology programs as well as CD24Fc, OncoImmune's lead candidate for the treatment of COVID-19
UCLA Health, Regeneron Genetics Center initiate research collaboration
The partners will conduct whole-exome sequencing on 150,000 patients in a partnership they say will advance personalized medicine
Patent Docs: What is required for an ANDA applicant to induce infringement?
GlaxoSmithKline LLC v. Teva Pharmaceuticals (Fed. Cir. 2020) addresses what quantum of culpable conduct is required
Bionano Genomics acquires Lineagen
Deal boosts capacity in digital cytogenetics and adds genetic diagnostics for neurodevelopmental disorders
An acquisition opportunity for CMOs?
Indian dose sites an untapped M&A opportunity for foreign contract manufacturers
Europital expands into a full-service CRO
New capabilities include project management, clinical monitoring and pharmacovigilance
A seed fund to drive biopharma innovation
Pistoia Alliance looks to finance four projects annually from idea to proof of concept
No more EUAs for COVID-19 tests
FDA makes a change in its policy of reviewing and granting tests related to the pandemic
Returning to the fold
Illumina acquires cancer-focused GRAIL for $8 billion
